COMP <GO>
MIDD vs TMO // RSI-14 & 200D SMA MOMENTUM
Middleby Corporation (The) (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: MIDD 6
— TMO 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MIDD
LAST: $118.95 (+1.16%) • MKT CAP: $5.32B
rsi-technicals
72.8
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
rsi-technicals
59.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIDD VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIDD | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.10% | 41.00% | -1.90 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.70% | 9.30% | +0.40 | MIDD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 30.4x | -19.00 | MIDD | /valuation <GO> |
| Free Cash Flow Yield | 10.52% | 2.40% | +8.12 | MIDD | /fcf-yield <GO> |
| Operating Margin | 18.00% | 17.40% | +0.60 | MIDD | /operating-margins <GO> |
| Net Profit Margin | 11.50% | 15.10% | -3.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 3.90% | -2.30 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.08 | 4.50 | -1.42 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.70% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 72.8 | 59.1 | +13.67 | MIDD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.94 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 36.3x | -22.80 | MIDD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.32B | $262.22B | -$256.90B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIDD REV | TMO REV | MIDD GROSS % | TMO GROSS % | MIDD FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.20B | $44.56B | 39.1% | 44.0% | $559.5M | $6.29B |
| FY 2024 | $3.15B | $42.88B | 39.7% | 44.0% | $650.1M | $7.27B |
| FY 2023 | $3.24B | $42.86B | 44.0% | 44.0% | $482.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIDD // BETA 0.94
TMO // BETA 0.94